Longevity & Peptide Clinic Malpractice Insurance

Your malpractice policy was probably written for the medicine you learned in residency, not the medicine you practice now.

If your clinic prescribes BPC-157, compounded semaglutide, NAD+ drips, exosomes, EBOO, pellets or rapamycin, one of those services may sit outside your current policy. Many clinics find out only after a claim is filed. We help physician practices, NP/PA-led clinics, and longevity, anti-aging, functional, integrative and regenerative clinics place coverage underwritten around the protocols they actually offer, subject to underwriting.

Peptide, IV, regenerative, oxidative and hormone protocols
Clinic, provider and medical director coverage
Products liability for clinics that sell peptides under their own brand
Coverage for longevity and peptide clinics starts at $8,500 per year, subject to underwriting

Request a quote with the form on this page

Standard NP or PA practice with no specialty protocols? Get an instant online quote →

Reviewed by Jeff Schmidt, 21 years in healthcare liability insurance, Arizona insurance license 9086805. Last reviewed October 29, 2026.

Labeled medication bottle used in a longevity and peptide clinic

Clinics We Work With: Longevity, Peptide, IV and Regenerative Practices

We work with prescribing practices, the clinics where a licensed provider makes the clinical decision:

Physician-owned longevity and concierge practices (MD/DO), including executive-health models
NP- and PA-led clinics with a collaborating physician or medical director
Anti-aging and age-management clinics
Functional and integrative medicine practices, including ND-inclusive clinics where state law allows
Regenerative and orthobiologic clinics (PRP, exosomes, cell-based therapies)
Hormone and men's/women's health clinics (TRT, BHRT, pellets)
Medical weight-loss and metabolic clinics (GLP-1 and peptide programs)
IV and infusion lounges that have added NAD+, ozone or high-dose protocols
Med spas that added a wellness or longevity menu
Telehealth longevity and peptide platforms with a defined prescribing model

Distribute or sell peptides wholesale or retail? That's a different exposure (mostly products liability). See our peptide distributor insurance guide or peptide retailer insurance.

Why a Good Malpractice Policy Can Still Leave a Longevity Clinic Uninsured

Most standard malpractice forms exclude claims arising from drugs, biologics or devices "not approved by the FDA," and many also exclude off-label and experimental treatments. In longevity medicine, that can describe half your menu.

The problem is usually not that your carrier is bad. It's that the policy form was built around FDA-approved drugs used on-label, in a conventional specialty. Longevity medicine runs into the exclusions in four places.

1. "Not approved by the FDA" exclusions. This is the big one. One malpractice exclusion upheld by a California appellate court reads, in part, that the insurer will not pay claims arising from "the use, administration or prescription of any drug … disapproved or not yet approved by the United States Food and Drug Administration for treatment of human beings" unless the insurer approved it in writing (California Court of Appeal, 1998). The court applied it to tea tree oil because the doctor used it as a drug. Compounded peptides, research-grade compounds, exosomes and most stem cell products fit that description far more clearly.

2. Off-label exclusions. Some endorsements exclude "the off label use of FDA approved drugs or devices" outright. Rapamycin for aging, metformin for healthspan, high-dose IV vitamin C, low-dose naltrexone, methylene blue and PRP joint injections are all off-label uses of approved products.

3. Experimental, investigational and named-procedure exclusions. Specimen endorsements in the market exclude named procedures such as "gas injection therapies," along with non-FDA-approved supplements and advertising that "guarantees" results. Brokers who specialize in this space report that separate stem cell and exosome exclusions are common.

4. The services you never listed. Every specialty application asks you to list your procedures. Many ask you to mark every drug and device as FDA-approved or not and describe any off-label use. If a protocol isn't on the application, assume the underwriter didn't price it, and the claims department may later argue it was never covered.

There's also a fifth gap that catches clinics that sell what they prescribe. Malpractice covers your professional judgment, not the product. If you dispense or sell peptides, supplements or compounded products, a claim that the product caused harm usually belongs under products liability, a different policy. If your clinic sells peptides under its own brand, we can place products liability alongside your malpractice, subject to underwriting.

2026 peptide update: what changed, and what didn't

Peptide regulation moved more in 2026 than in the previous three years, and underwriters are watching closely.

April 2026: FDA moved BPC-157, TB-500, CJC-1295, AOD-9604, epitalon, injectable GHK-Cu, KPV, Semax and several others off its "Category 2" (significant safety risk) list after the nominations were withdrawn. That did not make them FDA-approved. They weren't added to the 503A bulks list or to Category 1, and FDA kept its safety notes on immunogenicity, impurities and, for CJC-1295, cardiovascular reactions. Others, including thymosin alpha-1, kisspeptin-10 and Melanotan II, are still listed in Category 2.
July 23–24, 2026: FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157, TB-500, KPV, MOTS-c, epitalon and Semax to the 503A bulks list. It declined emideltide (DSIP). BPC-157 and TB-500 each passed 8–6. These votes were non-binding, and final rulemaking on the bulks list is still pending. Much of today's supply is "research use only," which no policy below covers.
October 28, 2026: HHS issued an interim enforcement-discretion policy letting 503A pharmacies compound those six peptides (BPC-157, TB-500, epitalon, KPV, MOTS-c and Semax) only under strict conditions: specified routes, a patient-specific prescription, a single active ingredient, and bulk substance from an FDA-registered, CGMP-compliant manufacturer with a certificate of analysis. It is not FDA approval and not a final rule. It doesn't cover 503B outsourcing facilities or research-chemical products, and HHS can withdraw it.
GLP-1s: FDA's shortage-based flexibility for compounded tirzepatide ended in February–March 2025 and for semaglutide in April–May 2025. FDA has warned about dosing errors and says salt forms (semaglutide sodium or acetate) are different ingredients from the approved drugs. Retatrutide is still investigational.

What this means for coverage: regulators are moving, but most standard policies still read the way they did. If you're adding peptides because the news sounds positive, confirm your coverage first. Last reviewed October 29, 2026.

Vials on a pharmaceutical production line, representing compounded drug sourcing

Peptide, NAD+, Ozone and Regenerative Protocols: What Underwriters Want

Every protocol below is one we can discuss with specialty markets. We help place coverage subject to underwriting. Availability, terms and exclusions depend on your state, providers, protocols and sourcing, and some protocols may be declined or excluded. Nothing here describes the safety or effectiveness of any treatment, and none of these uses is FDA-approved unless we say so.

Peptides and metabolic protocols

Compounded and "research" peptides BPC-157, TB-500, CJC-1295/ipamorelin, sermorelin, GHK-Cu (injectable), MOTS-c, epitalon, KPV, Semax/Selank, thymosin alpha-1, AOD-9604, kisspeptin, Melanotan II, PT-141 off-label - Why it's restricted: most aren't FDA-approved for these uses (PT-141 is approved only as Vyleesi for a specific indication). Several are or were on FDA's Category 2 safety list. Research-use-only (RUO) sourcing is common. Standard forms tend to exclude them under "not FDA-approved" wording. - What underwriters want to see: - a named peptide list with routes - a 503A or 503B pharmacy source, with no RUO or "not for human use" product - a prescription for an identified patient after a good-faith exam - peptide-specific consent that discloses FDA status - written medical director protocols - products liability if you dispense or sell (we can place it alongside your malpractice, including for clinics that sell peptides under their own brand)

Compounded GLP-1s and peptide weight loss Compounded semaglutide and tirzepatide, "microdosing" programs, salt forms, retatrutide ("reta") - Why it's restricted: FDA's enforcement discretion for copies of approved GLP-1s has ended. FDA has documented dosing errors and warned against salt forms, and retatrutide is investigational. Brokers report that carriers that write GLP-1 programs set narrow guardrails. - What underwriters want to see: - FDA-approved product, or a documented basis for a compounded version - the pharmacy name, with no salt forms or RUO product - a titration protocol and patient dose teaching (units vs mL) - contraindication screening and labs - a clear in-person vs telehealth model

Off-label longevity drugs Rapamycin/sirolimus, metformin, acarbose, senolytics (dasatinib + quercetin, fisetin) - Why it's restricted: these are approved drugs prescribed off-label to healthy adults, and some endorsements exclude off-label use outright. Underwriters focus on immunosuppression, myelosuppression and monitoring. - What underwriters want to see: off-label disclosure on consent, baseline and interval labs, written protocols, and prescriber credentials.

Low-dose naltrexone (LDN) and methylene blue - Why it's restricted: both are compounded or off-label. Methylene blue's only approved use is acquired methemoglobinemia, and its label carries a boxed warning for serotonin syndrome with SSRIs, SNRIs and other serotonergic drugs. It's also contraindicated in G6PD deficiency. - What underwriters want to see: medication reconciliation, G6PD screening where relevant, pharmaceutical-grade product (not industrial or aquarium grade), and dosing protocols.

IV and infusion protocols

NAD+ (IV, IM, subcutaneous, nasal) - Why it's restricted: NAD+ isn't an FDA-approved drug product. In 2024, FDA warned that compounders were making IV NAD+ from food-grade ingredients, with a high contamination and endotoxin risk. Infusion-rate reactions are a common complaint. - What underwriters want to see: a pharmacy-grade sterile source, an infusion-rate protocol, who places and monitors the line, a good-faith exam, and an emergency kit and plan.

IV micronutrients, high-dose vitamin C and glutathione Myers' cocktails, vitamin and amino acid pushes, high-dose ascorbate - Why it's restricted: - Most elective IV admixtures are off-label. - Injectable vitamin C is approved only for short-term treatment of scurvy, and its label warns of severe hemolysis in G6PD deficiency and of kidney injury at high doses. - In August 2026, FDA told compounders not to use supplement-grade glutathione in injectables. - States are tightening the rules. Texas's "Jenifer's Law" (effective Sept. 1, 2025) requires elective IV hydration to be ordered by a physician, or a PA or APRN under physician supervision. - What underwriters want to see: - a GFE or screening for new patients - G6PD testing before high-dose vitamin C - who orders and who administers - mobile vs in-clinic setting - pharmacy-sourced components - a written adverse-event plan

Chelation therapy EDTA, DMPS, DMSA "detox" protocols - Why it's restricted: no over-the-counter chelation product is FDA-approved, and FDA has warned about unproven products. The CDC has documented deaths from hypocalcemia during chelation. Cardiovascular "detox" uses are off-label, and specialty applications ask what share of your revenue comes from chelation. - What underwriters want to see: a documented indication, the agent used, calcium monitoring, an infusion protocol, and your revenue mix.

Ketamine IV/IM infusions, compounded troches and nasal sprays - Why it's restricted: ketamine is approved as an anesthetic, and its use for mood is off-label. FDA's October 2023 alert covered compounded ketamine for psychiatric use, including sedation, dissociation, blood pressure and breathing risks. It's a Schedule III controlled substance, and at-home and telehealth models draw extra scrutiny. - What underwriters want to see: in-clinic vs at-home, vital-sign and pulse-ox monitoring, ACLS or anesthesia credentials, DEA registration, psychiatric screening, and usually a separate supplemental application.

Blood-based and oxidative therapies

Ozone therapy, EBOO and major autohemotherapy EBOO/EBO2, MAH (10-pass and similar), prolozone, insufflation - Why it's restricted: federal regulation (21 CFR 801.415) states that ozone is "a toxic gas with no known useful medical application." In July 2025, FDA sent a warning letter to a manufacturer of EBOO and UV/ozone blood-treatment devices, calling them adulterated and misbranded. Procedural risks include air embolism, bleeding from anticoagulation and hemolysis. Some policy endorsements exclude "gas injection therapies" by name. - What underwriters want to see: - the exact modality, named (EBOO is not just "ozone") - device make and regulatory status - provider training and certification - anticoagulation and G6PD protocols - physician availability - an embolism and emergency plan - the state-law basis for the service.

Ultraviolet blood irradiation (UBI/UVBI) - Why it's restricted: blood is drawn, treated outside the body and reinfused, and FDA's July 2025 warning letter covered UV blood-irradiation devices too. - What underwriters want to see: everything on the EBOO list, plus device documentation.

Therapeutic plasma exchange and "young plasma" - Why it's restricted: apheresis is an invasive procedure normally done in hospitals, and using it for aging isn't an established indication. FDA has publicly warned that young-donor plasma infusions are unproven for aging and carry infection, allergic, lung-injury and cardiovascular risks. - What underwriters want to see: the setting and credentialing, apheresis-trained staff, the replacement fluid used, any trial or IRB status, and an emergency transfer plan.

Hyperbaric oxygen (HBOT), including "mild" soft-shell chambers - Why it's restricted: chambers are FDA-cleared only for specific medical conditions. FDA has said HBOT isn't cleared for many of the conditions it's marketed for, and it has flagged fire risk. - What underwriters want to see: chamber type and clearance, operator training, fire-safety procedures, pre-treatment screening, and physician oversight.

Regenerative and biologic therapies

Exosomes Injected, infused, or applied after microneedling or for hair restoration - Why it's restricted: FDA states there are currently no FDA-approved exosome products and has reported serious adverse events, including infections. Separate exosome exclusions are common. - What underwriters want to see: the product and vendor, the route (topical vs injected vs IV), lab testing documentation, how the service is advertised, and consent that discloses FDA status.

Stem cells, MSCs, SVF, and cord, Wharton's jelly or amniotic products - Why it's restricted: the only FDA-approved stem cell products are cord-blood cells for blood disorders. Products that are more than minimally manipulated, or used outside their natural function, generally need FDA approval or an IND. FDA has reported blindness, tumors and infections tied to unapproved products. - What underwriters want to see: - autologous vs allogeneic - vendors and testing (viral, bacterial, fungal) - same-day processing and chain of custody - conditions treated - IRB or trial participation - consent for every treatment - your advertising

PRP and PRF Joint, hair, aesthetic and sexual-wellness injections - Why it's restricted: PRP preparation devices are FDA-cleared for limited uses, and most office injections are off-label. Sexual-wellness injections are flagged as high-risk by many markets. - What underwriters want to see: the device used, indications, training, sterile technique, consent, and how much of your revenue PRP makes up.

Prolotherapy and regenerative injection therapy - Why it's restricted: these are off-label injections with procedural risk and limited supporting evidence. - What underwriters want to see: injector credentials, image guidance, indications and consent.

Gene therapies (follistatin, klotho) and offshore protocols - Why it's restricted: they aren't FDA-approved and are offered mainly at clinics outside the U.S. Most markets decline them outright. If your practice refers patients abroad or provides aftercare, disclose it. Your exposure doesn't stop at the border. - What underwriters want to see: any referral, monitoring or aftercare role. Expect a specific exclusion here, and we'll tell you plainly if that's the case.

Hormone optimization

Compounded BHRT and hormone pellets - Why it's restricted: a 2020 National Academies report found insufficient evidence for the safety and effectiveness of compounded "bioidentical" hormones. It singled out pellets and recommended limiting use to documented medical need. Applications list pellet insertion separately from other BHRT. - What underwriters want to see: FDA-approved vs compounded products, who inserts pellets, monitoring labs, and documented indications.

Testosterone replacement (TRT) - Why it's restricted: testosterone labels state that safety and efficacy aren't established for age-related low testosterone. FDA's 2025 class labeling update added blood-pressure warnings. It's a Schedule III controlled substance, and telehealth TRT models draw scrutiny. - What underwriters want to see: diagnostic labs, monitoring (hematocrit, PSA), the prescribing model, and the DEA and telehealth setup.

hCG - Why it's restricted: since March 2020, hCG has been regulated as a biologic and can't be compounded under the usual pathways. FDA says hCG isn't approved for weight loss. - What underwriters want to see: FDA-approved product only, a fertility or hypogonadism indication, and no hCG diet protocols.

Lower-acuity services underwriters still want listed

Photobiomodulation, red light and LLLT. Specific devices are FDA-cleared for specific uses, such as minor pain or pattern hair loss, and broader "cellular health" claims go beyond those clearances. These are usually simple to place, but only if they're on the application.

Also list: IV hydration, vitamin injections, cryotherapy, PEMF, infrared sauna, functional lab testing, supplements you sell, and any telehealth consults.

Nurse preparing an injection at a longevity clinic

What Longevity Clinic Malpractice Insurance Includes, and What Underwriters Ask

A properly built program usually has several parts working together. Which ones you need depends on whether you prescribe, administer, dispense or sell.

Medical professional liability that affirmatively schedules your protocols, so you aren't relying on silence in a standard form
Entity coverage for the clinic, LLC or PC, and for an MSO if you use one
Medical director and supervising-physician coverage, including the administrative, supervisory and good-faith-exam roles
Coverage for all providers: NPs, PAs, RNs, NDs where eligible, and contracted injectors
Products liability for anything you dispense or sell (peptides, supplements, compounded products). It's usually a separate policy from malpractice, and we can place it for clinics that sell peptides under their own brand, subject to underwriting
General liability for premises and bodily injury that isn't professional
Telehealth, including multi-state prescribing where you're licensed
Regulatory and license defense for medical, nursing and pharmacy board complaints
Cyber and HIPAA coverage for patient portals, telehealth and marketing data
Sexual misconduct and abuse coverage, often sublimited
The right policy form: claims-made vs occurrence, retroactive dates, prior acts and tail. This matters if you're moving from a standard policy to a specialty one.

Coverage for longevity and peptide clinics starts at $8,500 per year, subject to underwriting. Your premium depends on your providers, protocol mix, revenue, state and claims history.

The underwriting checklist: what to have ready

Clinics that come in organized get quoted faster and on better terms. Before you call, gather:

Your complete service menu, every protocol, including the ones you "only do occasionally"
A drug, peptide and device list with route, source pharmacy or manufacturer, and FDA status (approved, off-label, compounded or investigational)
Sourcing proof: 503A/503B pharmacy names, with no research-use-only product
Provider roster: licenses, DEA, board certifications, ozone/EBOO, IV or regenerative training certificates, and who does what
Medical director details: CV, written duties, chart-review cadence, collaboration or supervision agreements
Good-faith exam workflow and screening (G6PD, labs, contraindications)
Protocol-specific consent forms that disclose FDA status and off-label use
Emergency protocols: anaphylaxis, embolism, vasovagal, emergency transfer
Revenue by service line and patient volume
Telehealth model: states, patient location rules, prescribing workflow
Marketing: website and social claims. Avoid "guaranteed" or cure language, since some forms exclude it outright.
Current policy: declarations page, endorsements, retroactive date, and five-year loss runs

How Claims Tend to Happen (Illustrative Scenarios)

These are composite, hypothetical examples to show how coverage questions arise. They aren't real claims or clients, and the outcome of any claim depends on your actual policy wording.

The peptide that wasn't on the policy. A collaborating physician signs off on a clinic's injectable peptide protocol. A patient later alleges an injection-site infection and a systemic reaction. The clinic's standard policy excludes drugs "not approved by the FDA," and the peptide was never listed on the application. Defense costs start with no carrier responding.

The EBOO session. During an extracorporeal ozone session, a patient experiences a suspected air embolism and is transferred to the ER. The clinic's policy lists "IV therapy" but not EBOO, and an exclusion for gas injection therapies is attached. The coverage dispute becomes part of the lawsuit.

The pharmacy problem. A patient on a compounded GLP-1 is hospitalized after a dosing error, and the vial turns out to have come from a supplier using a salt form. The patient sues the prescriber, the clinic and the pharmacy. Whether the clinic is covered depends on its compounded-drug wording, and whether it also had products coverage.

The medical director who "just signed protocols." An NP-led clinic's medical director reviews charts monthly and is named personally after an exosome injection reaction. The director's own policy covers clinical practice, not medical-director duties at an outside entity.

Syringe and vial used for a peptide injection

Frequently Asked Questions

Does my standard malpractice policy cover peptides? Often it doesn't. Many policies exclude drugs that are not FDA-approved, and most peptides used in longevity medicine are compounded or unapproved. Some policies also exclude off-label use. Read your exclusions and endorsements, and confirm in writing that each peptide you use is covered. If it isn't, a specialty policy or endorsement written for that exposure may be available, subject to underwriting.

Did the 2026 FDA changes make BPC-157 and TB-500 legal or insurable? Not by themselves. In April 2026, FDA moved BPC-157, TB-500 and other peptides off its Category 2 list. In July 2026, an advisory committee recommended adding six peptides to the 503A bulks list, and in October 2026 HHS issued an interim policy that lets 503A pharmacies compound those six under strict conditions while rulemaking continues. None of this is FDA approval, and the policy can be withdrawn. Underwriters still look closely at sourcing, consent and protocols.

If I dispense or sell peptides, do I need more than malpractice? Usually, yes. Malpractice responds to claims about your professional judgment, such as selection, dosing and monitoring. A claim that the product itself was defective or contaminated generally falls under products liability, which is a separate coverage. Clinics that sell what they prescribe often need both, and we can place products liability for clinics that sell peptides under their own brand, subject to underwriting.

Are research-use-only peptides insurable? Generally, no. Specialty programs we have seen require pharmaceutical-grade or professional-use products dispensed through a licensed provider, and they exclude research-use-only and direct-to-consumer sales. If your clinic uses RUO product today, fix sourcing before applying.

Can EBOO, ozone or UV blood therapies be covered? Sometimes, through specialty markets, subject to underwriting. These therapies are high-scrutiny because of their FDA status and procedural risks. Underwriters want the exact modality named, along with device details, training, anticoagulation and emergency protocols, and the state-law basis for offering it. Some markets will decline or exclude these therapies.

Does the policy cover my NPs, PAs and medical director? It can, if it's built that way. A clinic program can schedule every provider and cover the entity, and medical director duties such as protocols, supervision and good-faith exams can be covered too. Many standalone physician policies cover clinical practice but not administrative or supervisory roles at another entity. Confirm both before your next renewal.

Should a longevity clinic choose claims-made or occurrence coverage? Many specialty longevity programs are written on a claims-made basis. What matters is keeping your retroactive date when you switch, and knowing how you'll buy tail coverage if you close or change carriers. If you are moving from a standard policy to a specialty one, coordinate the dates so there is no gap.

Can I get an instant online quote for a longevity clinic? Usually not. Protocols like peptides, exosomes and ozone need an underwriter to review your menu, sourcing and providers, so these programs are quoted by request. If you run a standard NP or PA practice without specialty protocols, you can use our instant online quote instead.

How much does longevity clinic malpractice insurance cost?
Coverage for longevity and peptide clinics starts at $8,500 per year, subject to underwriting. Your premium depends on your providers, protocol mix, revenue, state and claims history, and on whether you add products liability. Protocols that need extra underwriting review, such as ozone/EBOO, stem cells or ketamine, can affect price and terms.

Does malpractice insurance cover NAD+ IV therapy?
Not automatically. NAD+ is not an FDA-approved drug product, so it can fall under not-FDA-approved or experimental exclusions if it is not listed. Make sure NAD+ is scheduled by name with every route you use (IV, IM, subcutaneous). Underwriters want a pharmacy-grade sterile source, an infusion-rate protocol, a good-faith exam and an emergency plan, and mobile or in-home IV adds its own questions.

Can a new longevity clinic get coverage before it opens?
Yes, you can request a quote before you open, subject to underwriting. Underwriters price your planned service menu, providers, medical director arrangement and pharmacy sources, so have those documented. Bind coverage before your first patient, and list every protocol you plan to offer.

Get Coverage Built Around What You Actually Do

Tell us your protocols, and we'll tell you honestly what can be placed, what may be excluded, and what underwriters will want before they say yes. Coverage for longevity and peptide clinics starts at $8,500 per year, subject to underwriting. Specialty longevity programs are quoted individually, and we'll walk you through it.
Use the form below to submit a quote request
Standard NP or PA practice? Get an instant online quote →

Keep reading

NP & PA malpractice insurance for peptide prescribing: what's covered
Peptide protocols: the underwriting perspective
Informed consent for peptides: a practical template
Sourcing and compounding for peptide prescribers
GLP-1 exclusions: what to know before you start weight-loss injections
Functional medicine malpractice for integrative clinics
IV hydration clinic insurance · Med spa insurance guide
Selling peptides rather than prescribing them? Peptide distributor insurance guide
CarePro Insurance helps place coverage, subject to underwriting. Coverage availability, terms, limits, and exclusions vary by state, provider, protocol and sourcing, and are governed solely by the issued policy. This page is general information, not legal, regulatory or medical advice, and does not describe the safety or effectiveness of any treatment. Regulatory information reviewed October 29, 2026.